MiNK Therapeutics, Inc.

NASDAQ:INKT

Biotechnology

Healthcare
$10.22 -2.87%

-$0.35 today

Market cap
$52.17M
Beta
0.47
P/E (TTM)
-4.6
EPS (TTM)
-$2.60
52W Low $6.80High $76.00

Volume 0.01M

Average 0.05M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$5.93M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$14.72M

FY 2025 · Annual

+36.1% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(30.21M)(27.99M)(22.46M)(10.78M)(12.49M)
Depreciation & Amortization77.96K121.75K204.62K215.44K181.75K
Deferred Income Tax00000
Stock-Based Compensation1.74M3.03M3.86M1.81M2.67M
Change in Working Capital3.74M8.77M2.9M459.73K3.29M
Accounts Receivables00000
Inventory00000
Accounts Payables(152.04K)2.66M(1.92M)(1.18M)689.71K
Other Working Capital3.89M6.11M4.81M1.64M2.6M
Other Non-Cash Items11.83M(2.79M)(266.78K)(1.26M)424.63K
Operating Cash Flow(12.83M)(18.87M)(15.76M)(9.56M)(5.93M)
Capital Expenditures(248.98K)(250.05K)(73.56K)(4)0
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(248.98K)(250.05K)(73.56K)00
Debt Repayment9.46M005M0
Common Stock Issued39.8M005.8M14.9M
Common Stock Repurchased0(157.19K)(477.64K)00
Dividends Paid00000
Other Financing Activities1501.6K70.47K19.99K(173.35K)
Financing Cash Flow49.26M(155.6K)(407.17K)10.82M14.72M
Effect of Forex Changes16.9K19.39K(25.25K)(54.7K)(13.43K)
Net Change in Cash36.2M(19.25M)(16.27M)1.21M8.78M
Free Cash Flow(13.08M)(19.12M)(15.84M)(9.56M)(5.93M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$12.5M
+ D&A$181.7K
+ Stock-Based Comp$2.7M
+ Deferred Tax$0
+ Working Capital$3.3M
+ Other Non-Cash$424.6K
= Operating Cash Flow-$5.9M
- Capex$0
= Free Cash Flow-$5.9M

Analysis

FY2025 free cash flow is -$5.9M. FCF conversion is 47.4% of net income. Operating cash flow was -$5.9M, with capex of $0. The largest bridge item is Working Capital at $3.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 14, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026
4Statement of changes in beneficial ownershipSep 2, 2026

Does INKT generate free cash flow?

MiNK Therapeutics, Inc. (INKT) generated -$5.93M of free cash flow in fiscal 2025.

How much operating cash flow does INKT produce?

Operating cash flow was -$5.93M, before capital expenditures of $0.00.